The effects of somatostatin on oral glucose tolerance and on intestinal absorption of glucose and other nutrients have been studied in anaesthetised rats. Intravenous somatostatin (0.1-0.6 nmol/min) increased the rate of gastric emptying. After intraduodenal administration of glucose, the rise in peripheral plasma levels of the sugar was delayed, but finally exaggerated by somatostatin, which inhibited the insulin response. Absorption was evaluated by measuring the disappearance of radioactive nutrients from the lumen of a 'tied duodenojejunal loop'. At a luminal concentration of 4 mmol/l of 3-0-methylglucose, neither disappearance of the sugar from the lumen nor its appearance in plasma was affected by somatostatin. Passive transport of 3-0-methylglucose (100 mmol/l) was not significantly modified by somatostatin, although the appearance of the labelled tracer in plasma was delayed. Somatostatin had no significant effect on absorption of galactose (4 mmol/l), sucrose (40 mmol/l), le... Gut, 1982, 23, 140-145 Somatostatin and the intestinal transport of glucose and other nutrients in the anaesthetised rat C DAUMERIE AND J C HENQUIN From the Unite de Diabkte et Croissance, University ofLouvain School ofMedicine, Brussels, Belgium SUMMARY The effects of somatostatin on oral glucose tolerance and on intestinal absorption of glucose and other nutrients have been studied in anaesthetised rats. Intravenous somatostatin (0.1-0-6 nmol/min) increased the rate of gastric emptying. After intraduodenal administration of glucose, the rise in peripheral plasma levels of the sugar was delayed, but finally exaggerated by somatostatin, which inhibited the insulin response. Absorption was evaluated by measuring the disappearance of radioactive nutrients from the lumen of a 'tied duodenojejunal loop'. At a luminal concentration of 4 mmol/l of 3-0-methylglucose, neither disappearance of the sugar from the lumen nor its appearance in plasma was affected by somatostatin. Passive transport of 3-0-methylglucose (100 mmol/l) was not significantly modified by somatostatin, although the appearance of the
(100 mmol/l) was not significantly modified by somatostatin, although the appearance of the labelled tracer in plasma was delayed. Somatostatin had no significant effect on absorption of galactose (4 mmol/l), sucrose (40 mmol/l), leucine (4 mmol/l) or palmitate (0.1 and 0-4 mmol/l). These results show that somatostatin delays appearance of ingested sugars in peripheral plasma without direct effect on the absorption sites; this delay may result from changes in intestinal motility, enzyme secretion and splanchnic blood flow.
Studies by Gerich et al. have shown that intravenous administration of somatostatin to diabetic subjects improves their glucose tolerance after meals and oral glucose loads.' This phenomenon was attributed to inhibition ofglucagon release by somatostatin. Wahren and Felig, however, challenged this interpretation and suggested that somatostatin delays intestinal absorption of carbohydrates.2 Their proposal was based on the observation that in these diabetic subjects exogenous somatostatin markedly slowed the appearance of ingested xylose in peripheral plasma.
The hypothesis has been advanced that somatostatin, released during meals, could be a physiological regulator of the rate at which ingested nutrients enter the circulation.3 Several studies in humans and animals have been carried out to substantiate this proposal." '1 Conflicting results have appeared and their interpretation is not always straightforward. Thus, it is possible that somatostatin has no direct effect on the intestinal absorption itself, but slows the entry of nutrients in the blood by affecting gastric emptying,`4 intestinal motility,-"'7 gallbladder contraction,"8 digestive enzyme release,18-2" or splanchnic blood flow.22223
Received for publication 18 November 1981 In the present study, carried out in anaesthetised rats, we have investigated the influence of exogenous somatostatin on oral glucose tolerance and evaluated its possible effects on intestinal absorption of glucose and other nutrients.
Methods

ANIMALS
Experiments were performed in female Wistar rats (200-230 g) fasted for 18 hours. They were anaesthetised by an intraperitoneal injection of pentobarbital (30 mg/kg) followed, when required, by an additional intramuscular injection (6 mg/kg). Body temperature was maintained at 370C with a heating pad.
One jugular vein was cannulated for infusion of somatostatin, dissolved in physiological saline supplemented with 2-5 mg bovine serum albumin per ml. The doses of somatostatin were: a bolus of 1 nmol in 30 seconds, followed by an infusion of0-1 nmol/min or a bolus of 6 nmol followed by an infusion of 0-6 nmol/min.
Saline alone was similarly infused in control animals.
MEASUREMENT OF GASTRIC EMPTYING
A method slightly modified from the description of Poulakos and Kent2`was used. The abdominal cavity was opened and a loose ligature was placed around the 140 pylorus. Two millilitres of physiological saline, at 37 0C, containing 5 mg/ml polyvinylpyrrolidone (PVP) and a trace amount of 125I-PVP (30 nCi/ml), were introduced into the stomach through an oral catheter pushed just below the cardia. Thirty minutes later, the ligature around the pylorus was secured, another ligature was tied around the cardia, and the stomach was removed. After opening and washing, its content iǹ 25P-PVP was counted. Gastric emptying is defined as the percentage of 1251-PVP that has left the stomach after 30 (10 mmol/l) . When the concentration of glucose was 100 mmol/l, the concentration of NaCI was reduced to 80 mmol/l.
After 20 minutes, the loop was opened and washed with saline. The effluent radioactivity was collected in several fractions to which 10 ml Aqualuma (Lumac SA, Meise, Belgium) were added for determinationof the radioactive content. Correction of quenching was applied by the external standardisation method. The intestinal segment was then removed and dried before weighing. Net absorption was calculated from the difference between the infused and the recovered radioactivity. Taking into account the specific activity of the substance, absorption is expressed as gAmol of substance absorbed per g of dry intestine over 20 minutes.
Experiment protocols
One period ofabsorption Glucose or 3-0-methylglucose was introduced into the loop for 20 minutes and blood was taken from the tail vein to measure appearance of the labelled sugar in the circulation (100 g1 plasma into 10 ml Aqualuma). Somatostatin infusion started 10 minutes before introduction of the sugar and lasted until the end of the absorption period. In these experiments, the radioactivity remaining in the dried intestinal segment was determined after digestion of the tissue26. 
PRESENTATION OF RESULTS
Results are presented as means ± SEM and the statistical significance of differences between experimental groups was assessed using Student's t test for unpaired data, except where explicitly stated.
Results
EFFECTS OF SOMATOSTATIN ON GASTRIC EMPTYING
In control rats, gastric emptying after 30 minutes was 37.7 ± 3.5%. As shown by Fig. 1 , intravenous somatostatin accelerated (p < 0.005) the rate of emptying during perfusion of the hormone at the dose of 0.6 nmol/min.
EFFECTS OF SOMATOSTATIN ON GLUCOSE TOLERANCE
In control rats, introduction of glucose directly into the duodenum was followed by a rapid and marked increase in plasma glucose levels (Fig. 2) . They remained fairly stable from 15 to 45 minutes and then declined progressively. Simultaneously, the insulin levels increased promptly to a peak at 15 minutes and decreased regularly later on.
Twenty minutes after the start of somatostatin infusion, plasma insulin levels had decreased from 1 6 + 0.2 ng/ml to 0.9 ± 0.1 ng/ml (p < 0.01 by paired t test), but plasma glucose levels had not changed. After glucose administration, plasma glucose levels rose slightly less rapidly than in control animals (P < 0.025 at 15 minutes) and continued to increase regularly until 60 minutes. Thereafter they diminished but remained significantly higher than in rats which did not receive somatostatin. Somatostatin blunted the rise in plasma insulin levels and a rebound was observed when perfusion of the hormone was stopped (Fig. 2) .
EFFECTS OF SOMATOSTATIN ON APPEARANCE OF INGESTED SUGARS IN PERIPHERAL PLASMA
After introduction of a low concentration (4 mmol/l) of 3-0-methylglucose labelled with`C in the intestinal loop,`C activity was rapidly detectable in peripheral plasma (Fig. 3) . This kinetics was not modified by somatostatin, which was also without effect on the disappearance of the labelled sugar from the intestinal lumen (Fig. 3, right panel) .
When the concentration of 3-0-methylglucose was higher (100 mmol/l),`C activity in plasma rose steadily until the intestinal loop was opened and washed at 20 minutes (Fig. 3) . Somatostatin slowed down the appearance of the labelled sugar in plasma; the maximum was reached only at 30 minutes, after the loop had been opened and the perfusion of the hormone stopped. This effect of somatostatin was not accompanied by any significant difference in the disappearance of the sugar from the lumen. There was no difference between the mean dry weight of the intestinal loop in each group. At the end of the experiment, 0-7 ± 01% of the radioactive 3-0-methylglucose introduced into the lumen of control loops was recovered from the intestinal wall. In all animals, the first period was carried out during intravenous saline infusion, whereas the second period was carried out either during saline infusion (controls) or somatostatin infusion (0-6 nmol/min). absorption of glucose was fairly stable during the two periods and was not significantly modified by the perfusion of somatostatin. Galactose transport was also unaffected by somatostatin (Table) . Absorption of the glucose and fructose moieties of sucrose was inhibited by 74 ± 4% (n = 4), when intraluminal sodium was replaced by Tris, a known inhibitor of the sucrase.27 By contrast, intravenous somatostatin (Table) or intraluminal somatostatin (7.5 mmol/l; not shown) had no effect. Leucine transport was not affected by somatostatin, which reduced slightly the absorption of palmitate when the intraluminal concentration of the fatty acid was 0-4 mmol/l, but not when it was 0 1 mmol/l. In other experiments, palmitate (0.1 mmol/l) was dissolved with taurocholate; absorption was more important (0.46 ± 0.03 ,mol/g/20 min) than after emulsification of the fatty acid with albumin (Table) , but somatostatin, again, failed to affect this absorption (0.44 ± 0-02 ,umol/g/20 min).
Discussion
The idea that somatostatin could modulate intestinal absorption of nutrients stems from the observation2 that its intravenous administration delays the appearance of ingested xylose in peripheral blood. We could confirm this original observation with an infusion of only 0-6 nmol somatostatin/min to normal subjects (unpublished data). Surprisingly, however, detailed studies of the effects of somatostatin on oral glucose tolerance in non-diabetic subjects are rather few. It was briefly re-ported recently28 that, after oral glucose, plasma levels of the sugar rose more slowly during somatostatin infusion. Marco et al. 29 had shown earlier that, in nondiabetic gastrectomised patients, somatostatin causes a marked, but late impairment of the tolerance to oral glucose; during the initial 20 minutes, plasma glucose levels rose more slowly than during saline infusion. The same observation was made by Sakurai et al. 4 after intraduodenal glucose load in dogs. Our findings in normal rats (Fig. 2) are thus superimposable on those made in man and dog. The major difference is that we had to use much higher doses of somatostatin, which may be considered pharmacological. These were required, however, to mimic reliably an effect observed with lower doses in the two other species.
The possibility that a delay of gastric emptying by somatostatinl" plays a role in its effect on oral glucose tolerance is unlikely for two reasons. First, exogenous somatostatin accelerates gastric emptying in rat ( Fig.  1 ) and in man.28 Second, the slower rise in peripheral plasma glucose is also observed when glucose is administered directly in the duodenum in rats (Fig. 2 ) and dogs4 as well as in gastrectomised patients. 29 We found no evidence of a significant effect of exogenous somatostatin on carbohydrate absorption by a duodenojejunal loop in the anaesthetised rat. It is unlikely that mere technical problems inherent to this preparation account for the absence of effect. Thus, the validity of the method has already been assessed by others25 30 and, in our hands, is supported by various arguments: absorption rates were well reproducible during successive periods; active glucose transport could be inhibited by phlorizin or sodium omission; sucrose absorption was reduced when the sucrase activity was inhibited by Tris; histological examination of the loop showed good preservation at the end of the experiments. This lack of effect of exogenous somatostatin on carbohydrate transport in the rat intestine is in agreement with the recent report of Wilson et al.,"3 but contrasts with the inhibitory effect described by 12 Krejs et al. in man.
By contrast, somatostatin delayed the appearance in peripheral plasma of the non-metabolised 3-0-methylglucose introduced in the duodenum. In rats receiving doses of somatostatin slightly higher (1-2 nmol/min) than those used here, others`3 31 have failed to disclose any delay in the appearance of gut-derived sugars in peripheral blood. It is unlikely that this discrepancy is due to their use of an intestinal segment distal to the duodenojejunal junction, instead of the duodenojejunum in our case. The use of lower intraluminal concentrations of the sugars (0.02, 10, and 30 mmol/l) is probably more important Thus, such an effect of somatostatin was seen with the high (100 mmol/l), but not with the low intraluminal concentrations (4 mmol/l) of the sugars. These findings lend support to the hypothesis that the slower rise in plasma glucose after an oral load is really due to a delay in the appearance of ingested glucose in peripheral blood.
The infusion of somatostatin resulted in the expected decrease in plasma insulin levels and in a paradoxical delay in the rise of plasma glucose levels, without apparent difference in the disappearance of the sugar from the gut. In agreement with the conclusion arrived at by Wilson et al., '3 we believe that the reduction in splanchnic blood flow produced by somatostatin 2 22 23 might well explain our findings. The fact that we found no evidence of any difference in the radioactivity retained in the intestinal wall is not necessarily irreconcilable with these findings. Thus, these measurements were made 40 minutes after the end of somatostatin infusion and the opening of the loop. It is possible that some accumulation took place at earlier times; its reliable measurement was precluded, however, by the requirement to wash completely the bulk of intraluminal radioactivity.
In conclusion, our results show that, in the rat, somatostatin delays appearance of ingested sugars in peripheral blood without reducing their intestinal absorption. The somatostatin control of the rate at which nutrients enter the circulation3 is thus apparently not due to a direct effect on transport systems but rather seems to involve indirect mechanisms: an alteration of intestinal motility, an interference with the digestion of complex substrates by inhibition of the exdcrine pancreas and gall bladder function,"8-2 and an effect beyond the absorption sites, on the splanchnic vessels. 32 3 
